We have demonstrated for the first time that SGLT2 inhibitors alleviate nephrin loss and enhance TGF-β1 excretion in urine at the same time in type 2 diabetic patients with albuminuria. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.